Narrow Ruling in Bilski Is a Win for Dx Developers, Despite Ambiguity on Gene-Patent Questions

Many in the genetic testing industry have viewed the Bilski decision as a harbinger of the Supreme Court's thinking for future patent cases, including the anti-gene patenting suit filed against Myriad Genetics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.